| Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC … MJ Kersten, J Driessen, JM Zijlstra, WJ Plattel, F Morschhauser, ... Haematologica 106 (4), 1129, 2021 | 75 | 2021 |
| The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in 18F-FDG PET scans of patients with classical Hodgkin lymphoma J Driessen, GJC Zwezerijnen, H Schöder, EEE Drees, MJ Kersten, ... Journal of Nuclear Medicine 63 (9), 1424-1430, 2022 | 31 | 2022 |
| Extracellular vesicle miRNA predict FDG‐PET status in patients with classical Hodgkin Lymphoma EEE Drees, MGM Roemer, NJ Groenewegen, J Perez‐Boza, ... Journal of extracellular vesicles 10 (9), e12121, 2021 | 27 | 2021 |
| Primary therapy and relative survival in classical Hodgkin lymphoma: A nationwide population-based study in the Netherlands, 1989–2017 J Driessen, O Visser, JM Zijlstra, PJ Lugtenburg, WJ Plattel, MJ Kersten, ... Leukemia 35 (2), 494-505, 2021 | 19 | 2021 |
| Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced … AP Kater, MHJ van Oers, Y van Norden, L van der Straten, J Driessen, ... haematologica 104 (1), 147, 2019 | 13 | 2019 |
| Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP J Driessen, MJ Kersten, L Visser, A van den Berg, SH Tonino, JM Zijlstra, ... Leukemia 36 (12), 2853-2862, 2022 | 12 | 2022 |
| How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents J Driessen, SH Tonino, AJ Moskowitz, MJ Kersten Hematology 2021 (1), 240-246, 2021 | 9 | 2021 |
| Blood‐circulating EV‐miRNAs, serum TARC, and quantitative FDG‐PET features in classical Hodgkin lymphoma EEE Drees, J Driessen, GJC Zwezerijnen, SAWM Verkuijlen, JJ Eertink, ... EJHaem 3 (3), 908-912, 2022 | 4 | 2022 |
| Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory Hodgkin lymphoma: a large multi-trial analysis based on … J Driessen, F de Wit, AF Herrera, PLL Zinzani, AS LaCasce, ... Blood 138, 879, 2021 | 4 | 2021 |
| Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis J Driessen, F de Wit, AF Herrera, PL Zinzani, AS LaCasce, PD Cole, ... Blood advances 8 (11), 2740-2752, 2024 | 2 | 2024 |
| PREDICTIVE VALUE OF QUANTITATIVE 18F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN … J Driessen, GJC Zwezerijnen, H Schöder, AJ Moskowitz, MJ Kersten, ... Hematological Oncology 39, 2021 | 2 | 2021 |
| Baseline metabolic tumor volume in 18FDG-PET-CT scans in classical Hodgkin lymphoma using semi-automatic segmentation J Driessen, GJC Zwezerijnen, JJ Eertink, MJ Kersten, A Hagenbeek, ... Blood 134, 4049, 2019 | 2 | 2019 |
| Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma J Driessen, GJC Zwezerijnen, H Schöder, MJ Kersten, AJ Moskowitz, ... Blood advances 7 (21), 6732-6743, 2023 | 1 | 2023 |
| Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma J Driessen, WJ Plattel, L Visser, A Van Den Berg, JM Zijlstra, S Tonino, ... Blood 140 (Supplement 1), 9213-9215, 2022 | 1 | 2022 |
| P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on … J Driessen, F De Wit, AF Herrera, PL Zinzani, AS Lacasce, PD Cole, ... HemaSphere 6, 49, 2022 | | 2022 |
| LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY J Driessen, MJ Kersten, L Visser, A van den Berg, JM Zijlstra, SH Tonino, ... Hematological Oncology 39, 2021 | | 2021 |
| Determining the optimal segmentation method for assessing metabolic tumor volume in (18) FDG-PET-CT scans in relapsed/refractory classical Hodgkin lymphoma J Driessen, GJC Zwezerijnen, JJ Eertink, MJ Kersten, OS Hoekstra, ... European journal of nuclear medicine and molecular imaging 46 (SUPPL 1 …, 2019 | | 2019 |
| PF390 FIRST‐LINE TREATMENT WITH LENALIDOMIDE DOES IMPROVE OUTCOME IN ELDERLY/UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SYSTEMATIC REVIEW AND META‐ANALYSIS J Driessen, MJ Kersten, AP Kater HemaSphere 3, 147-148, 2019 | | 2019 |
| PF468 PRIMARY THERAPY AND RELATIVE SURVIVAL IN CLASSIC HODGKIN LYMPHOMA: A NATIONWIDE POPULATION‐BASED STUDY AMONG 9,367 ADULT PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 … J Driessen, O Visser, JM Zijlstra, PJ Lugtenburg, MJ Kersten, ... HemaSphere 3, 185, 2019 | | 2019 |
